List of Excipients in Branded Drug VUMERITY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Biogen Inc	VUMERITY	diroximel fumarate	64406-020	CARRAGEENAN
Biogen Inc	VUMERITY	diroximel fumarate	64406-020	CELLULOSE, MICROCRYSTALLINE
Biogen Inc	VUMERITY	diroximel fumarate	64406-020	CROSPOVIDONE
Biogen Inc	VUMERITY	diroximel fumarate	64406-020	HYPROMELLOSE
Biogen Inc	VUMERITY	diroximel fumarate	64406-020	MAGNESIUM STEARATE
Biogen Inc	VUMERITY	diroximel fumarate	64406-020	METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER

Vumerity Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Vumerity (diroximel fumarate) uses a conventional oral delayed-release capsule platform designed to deliver the active ingredient beyond the stomach and reduce gastrointestinal exposure. Its commercial differentiation comes primarily from the prodrug design and tolerability profile versus dimethyl fumarate, not from a novel excipient system. The principal excipient opportunities are therefore in enteric-release technology, capsule and coating manufacturing, bioequivalence support, supply-chain redundancy, and reformulations that preserve delayed release while improving administration or cost.

What is Vumerity and how does its excipient system work?

Vumerity is an oral disease-modifying therapy for relapsing forms of multiple sclerosis. The active ingredient, diroximel fumarate, is converted to monomethyl fumarate, the pharmacologically active metabolite. The product is supplied as 231 mg delayed-release capsules, with a recommended maintenance dose of two capsules twice daily after an initial titration period.[1]

The FDA labeling identifies the following inactive ingredients:

Component	Functional role
Microcrystalline cellulose	Diluent and structural carrier
Croscarmellose sodium	Disintegrant
Colloidal silicon dioxide	Glidant and flow aid
Talc	Processing aid and coating-related excipient
Magnesium stearate	Lubricant
Capsule shell materials	Hard gelatin shell, colorants and opacifying agents

The label confirms the presence of these excipients but does not provide a complete commercial manufacturing description of every layer, coating parameter, particle-size distribution, or process control used by Biogen and its manufacturing partners.[1]

The formulation objective is delayed release. Diroximel fumarate must pass through the stomach before drug release occurs. The release design limits gastric exposure and supports the product's gastrointestinal tolerability positioning against Tecfidera, which contains dimethyl fumarate.

How does Vumerity’s excipient strategy compare with Tecfidera?

Vumerity and Tecfidera share a fumarate-based pharmacological pathway, but their formulation strategies are not identical.

Attribute	Vumerity	Tecfidera
Active ingredient	Diroximel fumarate	Dimethyl fumarate
Dosage form	Delayed-release capsule	Delayed-release capsule
Active metabolite	Monomethyl fumarate	Monomethyl fumarate
Primary formulation objective	Delayed intestinal release and improved GI tolerability	Delayed intestinal release
Manufacturer	Biogen	Biogen
FDA approval	2019	2013
Reference product risk	Direct generic competition to Vumerity	Established generic competition to Tecfidera
Excipient differentiation	Limited public differentiation; release architecture is more important	Delayed-release capsule architecture

Tecfidera's generic pathway has already demonstrated that delayed-release fumarate products can attract substantial generic development activity. Vumerity benefits commercially from a distinct active ingredient and separate regulatory dossier, but its excipient platform remains vulnerable to development by manufacturers with experience in enteric capsules, coated multiparticulates, and pharmaceutical solid-dose bioequivalence.

Vumerity's commercial advantage is the combined effect of:

1. A distinct prodrug rather than dimethyl fumarate.
2. A delayed-release dosage form.
3. A clinical positioning based on improved gastrointestinal tolerability.
4. A relatively simple oral solid-dose manufacturing platform.

The fourth point is commercially important. Conventional excipients reduce manufacturing complexity and may lower technical barriers for generic or alternative suppliers.

What excipients are protected by Vumerity patents?

The public Vumerity patent estate is directed primarily to the active compound, pharmaceutical compositions, dosage forms, and methods of treatment. The FDA label does not establish which specific excipient combinations are claimed in granted patents.

The strongest formulation-related protection is likely to arise from claims covering:

• Diroximel fumarate compositions.
• Delayed-release pharmaceutical preparations.
• Oral dosage forms that control gastric exposure.
• Specific dissolution or release profiles.
• Treatment methods using diroximel fumarate.
• Manufacturing processes for producing the active ingredient or dosage form.

A generic manufacturer does not necessarily need to copy Biogen's excipient formula. It may develop a different composition that meets the same release, stability, and bioequivalence requirements. This limits the value of narrow excipient claims unless they are linked to a clinically meaningful dissolution profile or a difficult-to-reproduce product attribute.

Why conventional excipients do not eliminate patent risk

Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, talc, and magnesium stearate are widely used pharmaceutical excipients. Their individual use is unlikely to create a durable exclusivity barrier. Patent risk is more likely to depend on:

• The combination of excipients with diroximel fumarate.
• Coating composition and thickness.
• Acid resistance.
• Release onset and completion.
• Stability under humidity and temperature stress.
• Capsule fill weight and particle engineering.
• Manufacturing sequence and process controls.

A formulation patent can be commercially meaningful even when each excipient is off patent. The enforceable value comes from the claimed arrangement, process, or performance profile.

What is the Orange Book status of Vumerity?

Vumerity is approved under NDA 211855. FDA approval covers delayed-release capsules containing diroximel fumarate.[1] The FDA Orange Book is the controlling source for listed patents, regulatory exclusivity, and reference-product information.[2]

Vumerity should be analyzed through four separate exclusivity categories:

Exclusivity category	Relevance to Vumerity
New chemical entity exclusivity	Applies to the initial approval period for the active ingredient, subject to FDA determination
Patent exclusivity	Depends on patents listed for NDA 211855 and their expiration dates
Orphan-drug exclusivity	Not the primary basis of Vumerity’s relapsing multiple sclerosis approval
Pediatric exclusivity	Applies only if FDA grants the six-month extension after qualifying pediatric work

The practical entry date depends on the latest enforceable patent and any settlement terms, not only on the initial FDA exclusivity period. A patent listed in the Orange Book can create a 30-month stay if a generic applicant submits a Paragraph IV certification and the NDA holder files timely litigation.[3]

When does Vumerity lose exclusivity?

Vumerity loses commercial exclusivity in stages rather than on a single date.

Regulatory exclusivity

Vumerity was approved in October 2019. The initial five-year new chemical entity period, if applied in the ordinary manner, would have extended into 2024. NCE exclusivity prevents submission of an ANDA for the same active ingredient during the protected period, although it does not prevent all other regulatory pathways.[3]

The regulatory barrier does not determine the actual generic launch date. Patent challenges, litigation, settlements, pediatric extensions, and FDA review timing are more important after the NCE period ends.

Patent exclusivity

The relevant patent expiry dates depend on the specific patents listed for NDA 211855 and any patent-term adjustment or extension. Publicly associated Vumerity patent families include patents directed to diroximel fumarate and pharmaceutical compositions. Patent prosecution, continuation practice, and Orange Book listing decisions can produce multiple expiry dates.

A commercial diligence review should separate:

• Earliest possible ANDA approval date.
• Earliest non-infringing launch date.
• Expiration of composition patents.
• Expiration of formulation patents.
• Expiration of method-of-use patents.
• Any pediatric or patent-term extensions.
• Any settlement-based license date.

The earliest plausible generic launch is therefore a legal outcome, not a simple calculation from the 2019 approval date.

Which companies are challenging Vumerity?

Publicly visible generic challenges should be confirmed through FDA Orange Book entries, Paragraph IV notices, and federal court dockets. Generic companies that have developed fumarate products have an existing technical base in delayed-release oral solid dosage forms, but a Tecfidera generic approval does not automatically authorize a Vumerity generic.

The critical distinction is the active ingredient. Tecfidera contains dimethyl fumarate, while Vumerity contains diroximel fumarate. A company seeking approval of a Vumerity generic would generally need an ANDA referencing Vumerity and must establish pharmaceutical equivalence and bioequivalence for the diroximel fumarate product.

A Paragraph IV challenge could target:

• Invalidity of composition patents.
• Non-infringement of formulation claims.
• Obviousness of the delayed-release dosage form.
• Lack of written description or enablement.
• Improper Orange Book listing.
• Non-infringement of method-of-use patents through carve-outs.

No reliable conclusion about a particular challenger or litigation outcome should be drawn solely from generic activity involving Tecfidera.

What formulation patents could protect Vumerity?

Formulation patents are most valuable when they claim a product attribute that competitors cannot easily design around.

Delayed-release architecture

The core technical area is protection against gastric release. Claims may focus on:

• Enteric-coated particles.
• Acid-resistant polymer layers.
• Multiparticulate capsules.
• Delayed-release pellets or microtablets.
• Specific dissolution thresholds in simulated gastric fluid.
• Release in intestinal pH conditions.

A patent that claims only a familiar enteric polymer may have limited defensive value. A patent tied to a narrow release profile, stability result, or product performance may be stronger.

Excipient compatibility

Diroximel fumarate may require controls over moisture, thermal exposure, particle morphology, and contact with excipients. Potential commercial issues include:

• Drug-excipient degradation.
• Capsule-shell interaction.
• Lubricant concentration.
• Moisture migration.
• Coating cracking or pinholing.
• Dissolution changes during storage.

Stability-driven composition claims can support lifecycle management if the claimed excipient combination produces a measurable shelf-life or release advantage.

Manufacturing process claims

Process patents may protect:

• Granulation or blending sequence.
• Particle-size control.
• Coating conditions.
• Solvent selection.
• Drying conditions.
• Encapsulation parameters.
• In-process dissolution controls.

Process claims are particularly relevant for contract manufacturers and alternative suppliers. They can restrict manufacturing routes even when the final excipients are standard.

What commercial opportunities exist for excipient suppliers?

The largest opportunities are in platform technologies rather than commodity excipients.

Enteric and delayed-release polymers

Suppliers can target polymers and coating systems that deliver:

• Reliable acid resistance.
• Rapid release at intestinal pH.
• Low coating weight.
• Reduced defect rates.
• Improved scale-up.
• Compatibility with high-throughput capsule production.

Commercial value increases when the coating system produces a dissolution profile close to the reference product without requiring a complex manufacturing process.

Functional excipient systems

Pre-engineered blends containing filler, disintegrant, glidant, and lubricant can reduce formulation-development time. A supplier could offer a Vumerity-oriented platform for:

• Direct compression.
• Low-dose uniformity.
• Improved flow.
• Reduced lubricant sensitivity.
• Controlled capsule fill weight.
• Enhanced stability under humidity.

Such systems must be evaluated against reference-product dissolution rather than judged only by tablet or capsule manufacturing performance.

Capsule-shell technology

Capsule suppliers can compete on:

• Moisture control.
• Mechanical strength.
• Color consistency.
• Printing compatibility.
• Low extractables and leachables.
• Supply continuity.
• Vegetarian or non-gelatin alternatives.

A shell substitution would require regulatory assessment because shell composition can affect moisture transfer, mechanical performance, dissolution, and stability.

Analytical and bioequivalence support

The most defensible commercial opportunity may be technical services linked to excipient selection. Providers can support:

• Comparative dissolution testing.
• Biorelevant media testing.
• Acid-stage resistance studies.
• Excipient compatibility screening.
• Stability modeling.
• In vitro-in vivo correlation work.
• Generic formulation risk assessment.

These services can reduce development risk for companies pursuing an ANDA or an authorized-generic strategy.

What generic entry risks exist for Vumerity?

Vumerity faces a moderate technical barrier and potentially significant legal barriers.

Risk factor	Commercial assessment
Active ingredient	Higher barrier than a simple dimethyl fumarate copy because diroximel fumarate is distinct
Dosage form	Manageable; delayed-release capsules are established technology
Excipient availability	Low barrier; listed excipients are broadly available
Dissolution matching	Moderate barrier; release profile and stability must be reproduced
Patent risk	Potentially high, depending on active Orange Book listings
Manufacturing	Moderate barrier; coating and process control are important
Clinical differentiation	Vumerity’s tolerability positioning may support brand retention
Substitution dynamics	Depends on ANDA approval, state substitution rules, payer policy, and launch price

A first generic entrant could benefit from 180-day exclusivity if it is the first applicant with a qualifying Paragraph IV challenge. That incentive can increase the value of an early patent challenge and may produce settlement negotiations before final FDA approval.[3]

What licensing deals could create value around Vumerity?

Licensing opportunities are more likely to involve enabling technology than the core product. Relevant structures include:

• Licensing an enteric coating platform.
• Supplying proprietary capsule shells under a long-term agreement.
• Out-licensing a non-infringing generic formulation.
• Contract manufacturing of coated multiparticulates.
• Joint development of a lower-cost delayed-release product.
• Licensing analytical methods or dissolution-control technology.
• Commercializing an authorized generic after patent settlement.

Biogen’s principal commercial interest is likely to be supply reliability, lifecycle management, and protection of the Vumerity franchise. For a generic manufacturer, the most attractive target is a formulation route that avoids the strongest active-ingredient and formulation claims while preserving reference-product performance.

What FDA regulatory issues affect Vumerity excipient strategy?

FDA review of a Vumerity alternative would focus on pharmaceutical equivalence, bioequivalence, quality, and release performance. Key regulatory issues include:

• Same active ingredient and strength.
• Same dosage form and route of administration.
• Comparable delayed-release behavior.
• Comparable dissolution across relevant pH conditions.
• Stability through the proposed shelf life.
• Control of impurities and degradation products.
• Capsule-shell compatibility.
• Manufacturing reproducibility.
• Adequate labeling and product identification.

An excipient change can create regulatory risk even when the active ingredient is unchanged. Changes affecting release, absorption, tolerability, or stability may require additional studies. A generic applicant may use different inactive ingredients, but the resulting product must remain pharmaceutically equivalent and bioequivalent under the applicable FDA pathway.[3]

How strong is the Vumerity patent estate?

The estate is strongest where claims combine the active ingredient with a specific dosage-form or performance limitation. It is weaker where protection depends only on widely used excipients.

Stronger claim types

• Diroximel fumarate composition claims.
• Claims tied to specific delayed-release performance.
• Claims covering treatment methods that are difficult to carve out.
• Manufacturing claims that are necessary for commercial-scale production.
• Claims supported by clinical or stability advantages.

Weaker claim types

• Broad claims to standard fillers or lubricants.
• Generic enteric-coating claims.
• Claims covering routine capsule manufacture.
• Method-of-use claims that can be avoided through labeling.
• Narrow claims with multiple non-infringing formulation alternatives.

The practical strength of the estate depends on claim scope, prosecution history, validity record, listing status, and the ability of a generic applicant to design around the formulation.

What is the commercial outlook for Vumerity excipients?

Vumerity presents a targeted rather than broad excipient opportunity. Commodity excipient sales are unlikely to command significant strategic value because the listed materials are widely available. Higher-value opportunities exist in:

1. Delayed-release coatings with reproducible dissolution.
2. Moisture-managed capsule systems.
3. Functional excipient blends for direct-fill capsules.
4. Stability-enhancing formulations.
5. Analytical packages for generic development.
6. Contract manufacturing with validated coating capability.
7. Non-infringing lifecycle formulations.

The most attractive suppliers will combine excipient chemistry with process development, regulatory support, and supply assurance. A supplier selling only microcrystalline cellulose or magnesium stearate competes primarily on price. A supplier offering a validated delayed-release system can compete on development time, manufacturing yield, and regulatory execution.

Key Takeaways

• Vumerity uses a conventional excipient set in a delayed-release capsule.
• The commercial value lies in release control and tolerability, not in novel individual excipients.
• Diroximel fumarate is distinct from dimethyl fumarate, so Tecfidera generic approval does not establish Vumerity interchangeability.
• Formulation patents are most defensible when tied to dissolution, stability, or manufacturing performance.
• Generic entry risk depends on Orange Book patents, Paragraph IV challenges, litigation, settlements, and FDA review timing.
• Excipient suppliers should prioritize enteric coatings, capsule-shell systems, functional blends, and bioequivalence support.
• The strongest commercial position belongs to suppliers that can provide both materials and validated manufacturing processes.

FAQs

Can a generic Vumerity use different excipients?

Yes. A generic applicant may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling.

Is Vumerity an enteric-coated product?

Vumerity is labeled as a delayed-release capsule. The delayed-release performance requires protection from gastric release, but the public label does not disclose every proprietary coating parameter or manufacturing detail.

Can Tecfidera generic manufacturers automatically make Vumerity?

No. Tecfidera contains dimethyl fumarate, while Vumerity contains diroximel fumarate. A Vumerity alternative requires a separate regulatory submission and must address Vumerity-specific patents and product-performance requirements.

Which excipient is most commercially important in Vumerity?

The highest-value excipient technology is the delayed-release coating or coating system, because it controls acid resistance, intestinal release, dissolution, and potentially bioequivalence.

Does Vumerity have biosimilar risk?

No. Vumerity is a small-molecule oral drug, so the relevant competitive pathway is an ANDA or another small-molecule pathway, not a biosimilar application under the Public Health Service Act.

References

1. U.S. Food and Drug Administration. (2024). Vumerity (diroximel fumarate) delayed-release capsules: Prescribing information. Biogen Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions

4. Biogen Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.